New Study Hints At More Fosamax Problems

Law360, New York (July 15, 2008, 12:00 AM EDT) -- While the litigation over Fosamax continues to unfold, another clinical study has been released that suggests the osteoporosis drug may actually hinder bone growth and increase the possibility of fractures.

The study, conducted by physicians at Weill Medical College of Cornell University and published in the Journal of Orthopaedic Trauma, indicated that extended use of Fosamax and other bisphosphonates may increase the risk of femur fractures, News Inferno reported.

The study also revealed that long-term use of Fosamax can suppress bone metabolism, which reportedly restricts the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.